论文部分内容阅读
目的初步分析吉西他滨、紫杉醇联合顺铂(GTP)的化学疗法(化疗)方案在中国晚期尿路上皮癌患者的疗效及不良反应。方法收集2014年2月-7月期间在采用GTP方案化疗的晚期尿路上皮癌患者10例,按实体瘤的疗效评价标准1.1评价客观疗效收集不良反应。结果 10例晚期尿路上皮癌患者采用GTP方案进行一线化疗,完全缓解1例,部分缓解4例,稳定3例,进展2例。Ⅲ度的不良反应主要为血液学毒性,其中Ⅲ度白细胞或中性粒细胞下降5例,Ⅲ度贫血1例。其余不良反应包括胃肠道反应、脱发和肝肾功能异常等。结论 GTP方案治疗晚期尿路上皮癌近期疗效好,不良反应可控制,患者可耐受。
Objective To analyze the curative effect and adverse reactions of gemcitabine, paclitaxel combined with cisplatin (GTP) chemotherapy (chemotherapy) in patients with advanced urothelial carcinoma in China. Methods Ten patients with advanced urothelial carcinoma treated with GTP regimen between February and July 2014 were enrolled in this study. The objective efficacy was evaluated according to solid tumor efficacy evaluation criteria 1.1. Adverse reactions were collected. Results Ten patients with advanced urothelial carcinoma were treated with first-line chemotherapy with GTP regimen, with complete remission in 1 case, partial remission in 4 cases, stabilization in 3 cases and progression in 2 cases. Grade Ⅲ adverse reactions mainly hematological toxicity, including Ⅲ leukocyte or neutrophil decreased in 5 cases, Ⅲ degree anemia in 1 case. The remaining adverse reactions include gastrointestinal reactions, hair loss and liver and kidney dysfunction. Conclusions The GTP regimen is effective in the treatment of advanced urothelial carcinoma in recent years. The adverse reactions can be controlled and patients can tolerate it.